![Identification of Pyrrolo [2,3-b] Pyridine Derivatives as Novel JAK1 Inhibitors for the Treatment of Inflammatory Bowel Disease.](data:image/svg+xml,%3Csvg xmlns=%22http://www.w3.org/2000/svg%22 width=%22600%22 height=%22400%22 viewBox=%220 0 600 400%22%3E%3C/svg%3E)
Cure8 research brief
JAK1 inhibitors are an established therapeutic pathway in IBD; new, more selective small molecules could expand future treatment options. This study reports a novel compound with strong preclinical activity against inflammation in cell and mouse models.
Researchers working on IBD drug discovery, translational scientists, and clinicians interested in emerging IBD therapeutics and JAK-pathway research.
Researchers report designing and testing a series of pyrrolo[2,3-b]pyridine compounds as JAK1 inhibitors, using tofacitinib as the lead compound.
In laboratory assays compound 15 showed potent JAK1 inhibition (IC50 0.48 nM), reduced STAT1/3 phosphorylation in RAW264.7 cells, had favorable metabolic stability and oral bioavailability, and improved outcomes in a DSS-induced colitis mouse model including reduced TNF-α and IL-6 and promoted epithelial repair.
This is an abstract-level report of preclinical work (cell and mouse model) describing a candidate small-molecule JAK1 inhibitor. It does not report human clinical data or clinical safety in people. It describes drug-discovery and early efficacy signals that support further preclinical development.
If you follow treatment advances in IBD, this paper is early-stage/preclinical and indicates a new chemical series targeting the JAK pathway rather than an approved therapy. It is not evidence that the compound is available or proven safe in humans.
This record is an abstract/partial extraction of preclinical research (cell-based assays and a DSS mouse colitis model). Findings are preclinical and require further testing (toxicology, clinical trials) before any application to patient care. The source is an academic journal abstract.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Natural Science Foundation of the Jiangsu Higher Education Institutions of China - 24KJA350004 and 23KJB360016; Nanjing Science and Technology Plan Project - 202304009; Taizhou Natural Science Foundation - TZ202511
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Children with Crohn’s disease have fewer FDA‑approved advanced treatment options than adults, so clinicians and families often must choose among off‑label therapies with limited pediatric evidence.
This study examines a combination of ustekinumab plus low‑dose upadacitinib for patients with refractory Crohn’s disease — a group with limited options after failing anti‑TNF and single‑agent therapy. Results could...
This trial tests whether raising the upadacitinib dose to 45 mg can recapture clinical response in people with ulcerative colitis who lost response on the 30 mg maintenance dose. If effective and safe, the approach could...
